{"classes":[{"categories":[{"measurements":[{"comment":"Confidence interval cannot be calculated when there is only one subject.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"6.7"},{"comment":"The upper confidence bound could not be estimated because there were insufficient events beyond the median survival time.","groupId":"OG001","lowerLimit":"2.7","upperLimit":"NA","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.9","upperLimit":"27.5","value":"19.6"},{"groupId":"OG001","lowerLimit":"10.5","upperLimit":"23.0","value":"14.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"comment":"Confidence interval cannot be calculated when there is only one subject.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"6.0"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"18.2","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"NIH-required analysis. A disease event is defined as local/regional persistence or recurrence of the cancer under study, distant metastases, a new second primary cancer, or death due to any cause. Participants undergoing surgery who had an R2 resection and participants not undergoing surgery who had a positive endoscopic biopsy or no biopsy at all were considered to have local persistence of disease. Disease-free survival time is defined as time from randomization to the date of first disease event or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. Analysis was to occur after 162 events were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"OG000","title":"Chemoradiation and Trastuzumab (Arm 1)"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"OG001","title":"Chemoradiation (Arm 2)"}],"paramType":"MEDIAN","populationDescription":"Eligible randomized participants. Data were stratified by ethnicity.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 8.0 years.","title":"Disease-free Survival (DFS) by Ethnicity","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}